TRDA – entrada therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Entrada Therapeutics Reports First Quarter 2024 Financial Results
The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates [Yahoo! Finance]
Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Form 4 Entrada Therapeutics, For: May 08 Filed by: KIM PETER S
Form 10-Q Entrada Therapeutics, For: Mar 31
Form 8-K Entrada Therapeutics, For: May 07
Form 144 Entrada Therapeutics, Filed by: KREHER NERISSA
Form 144 Entrada Therapeutics, Filed by: KREHER NERISSA
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.